Forget it. I’m not going to waste my time reading Mercola’s bilge, and posting it is a waste of bandwidth. Nor will I go to his website; I don’t want my computer infected.
Seeing as how you are so protective of the continued profit of snake oil salesmen, I suspect you are raking in the dough yourself through those scams.
Accusing anyone who stands up for evidence based science of being a “Big Pharma” shill is extremely old and unimaginative. How about coming up with something new? Do you even have that amount of imagination?
funny how this article demonstrates exactly the opposite of what you stated about Vitamin C. #1 it is safe and #2 it works and #3 it is cheap - the nightmare for all the researchers whose income is derived from new drugs that do nothing and often cause harm. Note that in ancient Greece Pharmakon meant either "cure" or "poison"
Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937164/
Alpha A Fowler, III, Aamer A Syed, [...], and Ramesh Natarajan
Background
Parenterally administered ascorbic acid modulates sepsis-induced inflammation and coagulation in experimental animal models. The objective of this randomized, double-blind, placebo-controlled, phase I trial was to determine the safety of intravenously infused ascorbic acid in patients with severe sepsis.
Methods
Twenty-four patients with severe sepsis in the medical intensive care unit were randomized 1:1:1 to receive intravenous infusions every six hours for four days of ascorbic acid: Lo-AscA (50 mg/kg/24 h, n = 8), or Hi-AscA (200 mg/kg/24 h, n = 8), or Placebo (5% dextrose/water, n = 8). The primary end points were ascorbic acid safety and tolerability, assessed as treatment-related adverse-event frequency and severity. Patients were monitored for worsened arterial hypotension, tachycardia, hypernatremia, and nausea or vomiting. In addition Sequential Organ Failure Assessment (SOFA) scores and plasma levels of ascorbic acid, C-reactive protein, procalcitonin, and thrombomodulin were monitored.
Results
Mean plasma ascorbic acid levels at entry for the entire cohort were 17.9 ± 2.4 μM (normal range 50-70 μM). Ascorbic acid infusion rapidly and significantly increased plasma ascorbic acid levels. No adverse safety events were observed in ascorbic acid-infused patients. Patients receiving ascorbic acid exhibited prompt reductions in SOFA scores while placebo patients exhibited no such reduction. Ascorbic acid significantly reduced the proinflammatory biomarkers C-reactive protein and procalcitonin. Unlike placebo patients, thrombomodulin in ascorbic acid infused patients exhibited no significant rise, suggesting attenuation of vascular endothelial injury.
Conclusions
Intravenous ascorbic acid infusion was safe and well tolerated in this study and may positively impact the extent of multiple organ failure and biomarkers of inflammation and endothelial injury.
PS It works on exactly what we were discussing regarding Ebola: Sepsis Multiple organ failure Inflammation Hemorrhage